Molecular Monitoring of Chronic Myeloid Leukemia ChaoJie Zhen, Y. Lynn Wang The Journal of Molecular Diagnostics Volume 15, Issue 5, Pages 556-564 (September 2013) DOI: 10.1016/j.jmoldx.2013.05.010 Copyright © 2013 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions
Figure 1 Diagram of how BCR-ABL1 transcript levels change with tyrosine kinase inhibitor treatment over time. Responding patients experience a continuum of therapeutic milestones. CHR, complete hematological response; CMR, CMR representing 0.032%IS; Ctrl, control; MMR, MMR representing 0.1%IS. Asterisk, the 100% standardized baseline defined by the mean transcript level in a pool of 30 diagnostic CML specimens used in the IRIS trial (see Reference Materials). The Journal of Molecular Diagnostics 2013 15, 556-564DOI: (10.1016/j.jmoldx.2013.05.010) Copyright © 2013 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions
Figure 2 The principal steps of the RT-qPCR procedure. Most laboratories isolate total white blood cells by performing a simple step of red cell lysis (single asterisk). qPCR of BCR-ABL1 and the control gene are normally performed in parallel in the same run, and duplicate analysis of the standard curves, references, and patient materials is normally required for accurate quantification (double asterisks). The Journal of Molecular Diagnostics 2013 15, 556-564DOI: (10.1016/j.jmoldx.2013.05.010) Copyright © 2013 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions